Cost-Utility of Treatments for Pulmonary Arterial Hypertension: A Markov State-Transition Decision Analysis Model

Background and Objective: Clinicians must choose between an increasing number of medications for the treatment of pulmonary arterial hypertension (PAH) with different routes of administration, adverse effects, costs and efficacies. We constructed a decision analysis to help inform treatment choices...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical drug investigation 2009-01, Vol.29 (10), p.635-646
Hauptverfasser:	Garin, Margaret C., Clark, Leslie, Chumney, Elinor C. G., Simpson, Kit N., Highland, Kristin B.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antihypertensive Agents - economics Antihypertensive Agents - therapeutic use Cost-Benefit Analysis Decision Support Techniques Drug Costs Drug therapy Drug Therapy, Combination Health aspects Humans Hypertension, Pulmonary - drug therapy Hypertension, Pulmonary - economics Internal Medicine Markov Chains Medicaid - economics Medicare - economics Medicine Medicine & Public Health Original Research Article Pharmacology/Toxicology Pharmacotherapy Practice guidelines (Medicine) Pulmonary hypertension Quality of Life Quality-Adjusted Life Years Risk factors Sildenafil United States United States Food and Drug Administration
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!